|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.350 USD | +5.47% |
|
+7.14% | -19.16% |
| 06-29 | Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell Small Cap Comp Growth Benchmark | CI |
| 06-29 | Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 2000 Index | CI |
Company Valuation: Lineage Cell Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 336.6 | - | - |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -16.84% | - | - |
| Enterprise Value (EV) | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 336.6 | 336.6 | 336.6 |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -16.84% | 0% | 0% |
| P/E | -9.42x | -7.8x | -9.08x | -5.58x | -5.96x | -19.3x | -14.8x | 113x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.5x | 0.2x | -0x | 0.3x | -0.5x | -1x |
| Capitalization / Revenue | 95.1x | 13.5x | 21.3x | 11.7x | 27.8x | 18.8x | 18.6x | 5.64x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 18.8x | 18.6x | 5.64x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -13.5x | -13x | -11.1x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -13.9x | -13.4x | 44.4x |
| EV / FCF | - | 0x | -0x | -0x | -0x | -36.2x | -37.8x | 92.2x |
| FCF Yield | - | 0.32% | -15.3% | -21.4% | -4.8% | -2.76% | -2.64% | 1.08% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 | -0.07 | -0.0914 | 0.012 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.341 | 14.7 | 8.945 | 9.499 | 14.56 | 17.94 | 18.09 | 59.63 |
| EBITDA 1 | -48.34 | -21.79 | -24.04 | -20.87 | -35.92 | -24.88 | -25.87 | -30.42 |
| EBIT 1 | -49.21 | -22.52 | -24.73 | -21.48 | -36.62 | -24.28 | -25.17 | 7.576 |
| Net income 1 | -43.02 | -26.27 | -21.49 | -18.61 | -63.53 | -23.79 | -31.66 | 6.948 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 2.450 | 1.170 | 1.090 | 0.502 | 1.670 | 1.350 | 1.350 | 1.350 |
| Nbr of stocks (in thousands) | 168,558 | 169,976 | 174,987 | 220,416 | 242,328 | 249,298 | - | - |
| Announcement Date | 3/10/22 | 3/9/23 | 3/7/24 | 3/10/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -18.29x | - | - | - | 319M | |
| 32.21x | 5.68x | 17.59x | 1.02% | 46.2B | |
| -22.9x | 343.72x | -21.86x | -.--% | 38.71B | |
| 23.26x | 2.64x | 11.39x | -.--% | 31.9B | |
| 41.76x | 4.18x | 26.75x | -.--% | 31.12B | |
| 27.93x | 7.24x | 18.62x | 0.45% | 23.77B | |
| 30.92x | 5x | 22.8x | -.--% | 15.05B | |
| 23.95x | 2.04x | 8.96x | 1.12% | 13.74B | |
| -22.52x | 14.77x | -22.09x | -.--% | 13.42B | |
| Average | 12.92x | 48.16x | 7.77x | 0.32% | 23.8B | |
| Weighted average by Cap. | 17.71x | 66.64x | 8.30x | 0.34% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LCTX Stock
- Valuation Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
